Work

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

Year: 2016

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood.v128.22.905.905

Authors: Guillermo Garcia-Manero, Michael R. Savona, Steven D. Gore, Bart L. Scott, Christopher R. Cogle, Thomas Boyd, Paul Conkling, Joel Hetzer, Qian Dong, Keshava Kumar, Stacey M. Ukrainskyj, Barry S. Skikne

Institutions: The University of Texas MD Anderson Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Yale Cancer Center, Fred Hutch Cancer Center, University of Florida, Willamette Valley Cancer Institute and Research Center, Virginia Oncology Associates, Celgene (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2771841126

Cites:

Cited by: 10

Related to: 10